Cargando…
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
This 7-day randomized, double-blind, placebo-controlled fixed-dose study (NCT03766867) explored the potential for accelerating the onset of antidepressant efficacy of single-dose intravenous (IV) vortioxetine at oral vortioxetine treatment initiation. Patients (ages 18–65 years) hospitalized per sta...
Autores principales: | Rancans, Elmars, Zambori, Janos, Dalsgaard, Mads, Baayen, Corine, Areberg, Johan, Ettrup, Anders, Florea, Ioana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531504/ https://www.ncbi.nlm.nih.gov/pubmed/32784346 http://dx.doi.org/10.1097/YIC.0000000000000326 |
Ejemplares similares
-
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study
por: Vieta, Eduard, et al.
Publicado: (2019) -
Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019) -
Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017) -
Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals
por: Areberg, Johan, et al.
Publicado: (2014) -
Efficacy of vortioxetine on the physical symptoms of major depressive
disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)